ANI Pharmaceuticals (NASDAQ:ANIP) Announces Earnings Results

Posted by Stanley Muller on Aug 7th, 2026

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) announced its quarterly earnings results on Friday. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, beating analysts’ consensus estimates of $2.04 by $0.17, FiscalAI reports. The company had revenue of $266.04 million for the quarter, compared to analyst estimates of $260.13 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. ANI Pharmaceuticals’s revenue for the quarter was up 25.8% on a year-over-year basis. During the same quarter last year, the business earned $1.80 EPS. ANI Pharmaceuticals updated its FY 2026 guidance to 9.190-9.690 EPS.

Here are the key takeaways from ANI Pharmaceuticals’ conference call:

ANI reported record second-quarter revenue of $266 million, up 26% year over year, with adjusted EBITDA up 32% to a record $71.6 million and operating cash flow of $56.7 million.
The company modestly lowered 2026 Cortrophin Gel revenue guidance to $520 million-$540 million, citing first-half performance, although it maintained expectations for strong second-half growth and reaffirmed total revenue guidance of $1.08 billion-$1.14 billion.
Cortrophin revenue rose 43% year over year to $117.1 million, while the gout-focused sales-force expansion is showing encouraging early indicators: more than 95% of new representatives generated multiple cases and over one-third of prescribers initiated at least two cases.
Generics revenue increased 10% to $99.1 million, with 12 products launched year to date and at least 15 expected for 2026; management also highlighted that approximately 95% of revenue comes from products manufactured in the U.S.
ILUVIEN revenue declined 16% year over year to $18.7 million, primarily due to international shipment timing, though management reaffirmed its full-year guidance and expects more detailed uveitis trial data in the fourth quarter.

ANI Pharmaceuticals Stock Performance

ANIP stock traded down $4.38 during trading on Friday, hitting $78.25. 1,020,050 shares of the company’s stock traded hands, compared to its average volume of 293,035. The stock has a market capitalization of $1.78 billion, a price-to-earnings ratio of 19.81 and a beta of 0.44. ANI Pharmaceuticals has a 52 week low of $70.15 and a 52 week high of $99.50. The stock has a fifty day moving average price of $81.02 and a two-hundred day moving average price of $79.37. The company has a quick ratio of 2.52, a current ratio of 3.12 and a debt-to-equity ratio of 1.06.

Key Headlines Impacting ANI Pharmaceuticals

Here are the key news stories impacting ANI Pharmaceuticals this week:

Positive Sentiment: Second-quarter adjusted earnings per share were $2.21, exceeding the roughly $2.01-$2.04 consensus range, while revenue of $266.0 million surpassed estimates near $260 million. Revenue increased 25.9% year over year, and adjusted EBITDA rose 32.4% to $71.6 million. ANI Pharmaceuticals Q2 Earnings and Revenues Beat Estimates
Positive Sentiment: Purified Cortrophin Gel revenue climbed 43.5% to $117.1 million. Management said the expansion into podiatrists and primary-care physicians for acute gout was fully operational by June, with encouraging early prescribing and patient-case trends. ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results
Positive Sentiment: ANI reaffirmed full-year 2026 revenue guidance of $1.08 billion-$1.14 billion, adjusted EBITDA of $285 million-$300 million and adjusted EPS of $9.19-$9.69, above the prior consensus EPS estimate of $9.10. The company also has authorization for up to $100 million in share repurchases through May 2029. ANI Pharmaceuticals Reports Second-Quarter 2026 Results
Neutral Sentiment: Generics revenue increased 9.7% to $99.1 million, supported by new launches, while ANI reported 12 generic launches year to date and remains on track for at least 15 in 2026.
Negative Sentiment: ANI reduced its 2026 Cortrophin Gel revenue target to $520 million-$540 million from $540 million-$575 million. Although the revised range still implies 50%-55% growth, the cut may have disappointed investors expecting stronger near-term performance.
Negative Sentiment: Gross margin fell to 62.4% from 64.7%, partly because of a greater mix of royalty-bearing products. Selling, general and administrative costs rose 12.1% as ANI expanded its rare-disease sales force for the gout opportunity.
Negative Sentiment: ILUVIEN revenue declined 16.1% to $18.7 million because of international shipment timing, while Brands revenue fell 10.5% amid normalized demand.

Insider Buying and Selling

In other news, CFO Stephen P. Carey sold 3,313 shares of ANI Pharmaceuticals stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $86.00, for a total value of $284,918.00. Following the completion of the transaction, the chief financial officer directly owned 177,543 shares of the company’s stock, valued at approximately $15,268,698. The trade was a 1.83% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ori Gutwerg sold 2,772 shares of the business’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $79.50, for a total transaction of $220,374.00. Following the sale, the senior vice president directly owned 78,696 shares of the company’s stock, valued at approximately $6,256,332. This represents a 3.40% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 88,029 shares of company stock worth $6,954,472. Company insiders own 8.10% of the company’s stock.

Hedge Funds Weigh In On ANI Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Advisors Asset Management Inc. acquired a new position in ANI Pharmaceuticals during the 1st quarter valued at approximately $28,000. Kemnay Advisory Services Inc. bought a new position in ANI Pharmaceuticals during the 4th quarter worth $48,000. State of Wyoming acquired a new stake in ANI Pharmaceuticals in the second quarter worth $50,000. Tower Research Capital LLC TRC increased its position in ANI Pharmaceuticals by 542.0% in the second quarter. Tower Research Capital LLC TRC now owns 1,727 shares of the specialty pharmaceutical company’s stock worth $113,000 after buying an additional 1,458 shares during the period. Finally, Maryland State Retirement & Pension System lifted its stake in ANI Pharmaceuticals by 5.4% in the fourth quarter. Maryland State Retirement & Pension System now owns 2,613 shares of the specialty pharmaceutical company’s stock valued at $206,000 after buying an additional 134 shares during the last quarter. 76.05% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms recently commented on ANIP. Canaccord Genuity Group started coverage on shares of ANI Pharmaceuticals in a report on Thursday, July 16th. They issued a “hold” rating and a $91.00 price target on the stock. Guggenheim restated a “buy” rating and set a $124.00 price objective on shares of ANI Pharmaceuticals in a research note on Friday, July 10th. Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Finally, Weiss Ratings upgraded ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, June 23rd. Six research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $105.00.

Check Out Our Latest Stock Analysis on ANI Pharmaceuticals

About ANI Pharmaceuticals

(Get Free Report)

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.